MAMahya Assadipapari

Mahya Assadipapari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mahya Assadipapari has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Size- and Geometry-Dependent pH-Responsive Nanochannel Membranes Functionalized with Glycine and Pentylamine

    by Songbai Cao, Mahya Assadipapari, Yuan Xu, Youjian Liu, Mingyi Yu, Jun Peng, Lingzhi Xiao, Yifan Yang, Yuhua Cai, Sebastien Balme, et al.

    Artificial membranes are widely used to mimic the selective transport behavior of biological ion channels and pumps, particularly their stimulus-responsive regulation capabilities. Herein, solid-state nanochannels are chemically functionalized with glycine (Gly) and pentylamine to precisely tune interfacial chemistry and surface charge states. Owing to distinct pore sizes and geometric confinement, cylindrical and conical nanochannels exhibit markedly different pH-responsive ion transport mechanisms. In cylindrical nanochannels with relatively large diameters, ion transport is dominated by bulk ionic conduction, and the pH dependence mainly arises from the different mobilities of H+ and OH– ions. In contrast, conical nanochannels with narrow tips display surface-charge-governed transport, where pH and salt concentration jointly modulate electric double layer overlap and ion current rectification. Under acidic conditions, the functionalized nanochannels show suppressed ionic conduction associated with a hydrophobic interfacial state, while alkaline environments induce enhanced conduction due to increased surface charge density and wettability. These results establish a geometry-dependent pH-gating mechanism, providing a rational design strategy for responsive ion-transport membranes in sensing and separation applications.

  • Open Access

    Tracking single-molecule ferritin reassembly and disassembly using polymer-coated nanopores

    by Mahya Assadipapari, Alireza Soleimanian, Max Adam, Jiali Li, Arman Yousefi, Saaman Zargarbashi, Lei Xu, Max F. K. Wills, Hesna Kara, Marina Santana Vega, et al.

    This study uses polymer-coated SiN x nanopores and individual-event data analysis to track real time volume and shape changes of ferritin fragments during reassembly and disassembly, offering a powerful method for probing dynamic protein processes.


  • Open Access

    Cryo-EM led analysis of open and closed conformations of Chagas vaccine candidate TcPOP

    by Sagar Batra, Francisco Olmo, Timothy J. Ragan, Merve Kaplan, Valeria Calvaresi, Asger Meldgaard Frank, Claudia Lancey, Mahya Assadipapari, Cuifeng Ying, Weston B. Struwe, et al.

    Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, remains a significant global public health concern. Despite its profound health impact in both endemic and non-endemic areas, no vaccine is available, and the existing therapies are outdated, producing severe side effects. The 80 kDa prolyl oligopeptidase of Trypanosoma cruzi (TcPOP) has been identified as a leading candidate for Chagas vaccine development. Here we report the three-dimensional structure of TcPOP in open and closed conformation, at a global resolution of 3.8 and 3.6 Å, respectively, determined using single-particle cryo-electron microscopy. Multiple conformations were observed and further characterized using plasmonic optical tweezers and hydrogen-deuterium exchange mass spectrometry. To assess the immunogenic potential of TcPOP, we immunized female mice and evaluated both polyclonal and monoclonal responses against the TcPOP antigen and its homologues. The anti-TcPOP polyclonal response demonstrates invasion blocking properties via parasite lysis. Polyclonal sera were cross-reactive with closely-related POPs but not with human homologues. Collectively, our findings provide structural and functional insights necessary to understand the immunogenicity of TcPOP for future Chagas vaccine development.